Trial Profile
A Phase 2, Multi-Center, Open Label Study to Evaluate Adenoviral p53 (Ad-p53) in Combination With Immune Checkpoint Inhibitor Therapy in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma and Other Tumors Approved for Anti-PD-1 or Anti-PD-L1 Therapy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs P53 gene therapy - MultiVir (Primary) ; Atezolizumab; Durvalumab; Nivolumab; Pembrolizumab; Programmed cell death-1 receptor antagonists
- Indications Head and neck cancer; Lymphoma; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors MultiVir
- 05 Jun 2020 Planned End Date changed from 1 May 2022 to 31 Dec 2022.
- 05 Jun 2020 Planned primary completion date changed from 1 Oct 2021 to 30 Jun 2022.
- 03 Jun 2020 Planned number of patients changed from 20 to 40.